Combining clinical trial data for corneal collagen cross linking to accelerate FDA process

Article

Avedro and Emery University have entered into an agreement to combine clinical trial data for corneal collagen cross-linking.

Avedro and Emery University have entered into an agreement to combine clinical trial data for corneal collagen cross-linking. The organisations’ are both looking a the safety and efficacy of riboflavin and ultraviolet-A light for halting the progression of keratoconus and post-LASIK ectasia and the associated deterioration in patient’s decline as a result of these disorders.

Dr Peter Hersh, professor of ophthalmology at UMDNJ – New Jersey Medical School and director of Cornea and Laser Eye Institute – CLEI Centre for keratoconus said: “The primary goal of collagen crosslinking is to strengthen and stiffen the corneal fibers in order to decrease the progression of keratoconus and post LASIK ectasia and to decrease the cone steepness in some patients. The safety ad efficacy of crosslinking, as demonstrated in the Avedro clinical studies is very encouraging.”

Dr J. Bradley Randelman, Associate Professor of Ophthalmology Section of Cornea, External Disease and Refractive Surgery at Emory University stated: “Our aim, in permitting Avedro to combine our clinical study results with its own, is to help Avedro expedite its NDA submission to the FDA. The more quickly the FDA can begin to review the results of this promising technology, the more quickly it can make a determination as to its safety and efficacy.”

Recent Videos
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
© 2025 MJH Life Sciences

All rights reserved.